JPRN-jRCT2080221664招募中3 期
A 52-Week, Open-Label, Long-Term Safety Study of LY2189265 in Combination With Monotherapy of Oral Antihyperglycemic Medications in Patients With Type 2 Diabetes Mellitus
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •Patients who have had a diagnosis of type 2 diabetes mellitus before screening
- •Patients who have been taking SU (Glibenclamide, Gliclazide, Glimepiride), biguanides, TZD, a-GI or glinides monotherapy for at least 3 months before screening and have been on a stable dose for at least 8 weeks before screening
- •Patients must have a qualifying HbA1c value of 7.0% to 11.0% at screening
- •Patients who have a body mass index (BMI) of 18.5 kg/m2 to 35.0 kg/m2
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
Evaluation of long term safety of LY2951742 in Patients with MigraineEpisodic or chronic migraine headacheEUCTR2015-001884-38-HUEli Lilly and Company312
招募中
3 期
A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 (Galcanezumab) in Japanese Patients with MigraineMigraineJPRN-jRCT2080223375Eli Lilly Japan K.K.
进行中（未招募）
1 期
Evaluation of long term safety of LY2951742 in Patients with MigraineEUCTR2015-001884-38-BEEli Lilly and Company312
进行中（未招募）
1 期
Evaluation of long term safety of LY2951742 in Patients with MigraineEpisodic or chronic migraine headacheEUCTR2015-001884-38-FREli Lilly and Company270
进行中（未招募）
1 期
A Long-Acting Growth Hormone (Somavaratan, VRS-317) in ChildreEUCTR2016-002780-34-SEVersartis, Inc.400